Neurofibromatosis is a group of genetic conditions. In these conditions, small mistakes in certain genes make cells in nerves grow in the wrong way. This can lead to benign (non-cancer) tumors on nerves and other health issues. These tumors often grow slowly. Many people live full lives with NF, but some people need regular medical care to watch for problems and treat them early. Doctors use updated international criteria to diagnose the different NF types, and these criteria now also use genetic testing when needed. NCBINaturePubMed

Neurofibromatosis is a group of inherited conditions that make a person more likely to grow nerve-related tumors. Most of these tumors are benign (non-cancerous), but some can press on nearby structures and cause problems such as pain, weakness, vision or hearing loss. There are three main forms:

• NF1 (the most common): often shows café-au-lait spots on the skin, freckles in the armpits/groin, and soft skin-colored bumps called cutaneous neurofibromas; some people develop deeper plexiform neurofibromas, bone changes (for example scoliosis), learning/attention issues, high blood pressure, and eye findings. NF1 is autosomal dominant (each child of an affected parent has a 50% chance to inherit it), and about half of people with NF1 are the first in their family due to a new variant. PMC

• NF2-related schwannomatosis (formerly “NF2”): the hallmark is bilateral vestibular schwannomas (tumors on the hearing/balance nerves) leading to tinnitus, hearing loss, and balance problems. People can also develop other schwannomas, meningiomas, and spinal tumors. It’s also autosomal dominant; many cases are new in a family. NCBI

• LZTR1- and SMARCB1-related schwannomatosis: people develop multiple schwannomas (nerve-sheath tumors) in the body, often with significant pain; vestibular schwannomas are uncommon except in NF2-related disease. These conditions also run in families with reduced penetrance. NCBI

Types of Neurofibromatosis

1) Neurofibromatosis type 1 (NF1).
NF1 is the most common type. It often shows up in childhood with light-brown skin spots (café-au-lait macules), tiny freckles in the underarm or groin, and small skin bumps called neurofibromas. The gene involved is called NF1, which helps control cell growth through the RAS/MAPK pathway. Doctors use the 2021 revised NF1 criteria, which include skin signs, eye signs, bone changes, tumors like optic pathway glioma, and/or a confirmed NF1 gene variant. NCBINature

2) NF2-related schwannomatosis.
This condition used to be called “NF2.” The new name reflects that the main problem is multiple schwannomas (tumors of the nerve sheath), especially on the balance/hearing nerves (vestibular nerves). Typical features include hearing loss, tinnitus, and balance trouble from vestibular schwannomas. The gene is NF2, which makes the merlin protein that helps stop uncontrolled growth. Updated 2022 criteria and naming were published by an international group. NCBIPubMed

3) Other forms of schwannomatosis (not NF2-related).
Some people develop multiple schwannomas because of changes in other genes, such as SMARCB1 or LZTR1. These forms usually do not cause vestibular schwannomas on both sides. They often present with chronic nerve pain from tumors along peripheral nerves. The current system names them by the gene involved (e.g., SMARCB1-related schwannomatosis, LZTR1-related schwannomatosis). PubMed

4) Mosaic forms.
Some people have the gene change in only part of the body. This is called mosaic NF1, mosaic NF2-related schwannomatosis, or mosaic SMARCB1/LZTR1-related schwannomatosis. Signs can be patchy or one-sided because only some cells carry the change. Doctors recognize mosaic forms in all NF categories. PubMed

Note: Legius syndrome can look like mild NF1 (with café-au-lait spots and freckling) but does not cause neurofibromas or optic gliomas. It is due to the SPRED1 gene and has its own criteria. Doctors check for this when NF1 features are limited to pigment changes. Nature

---

Causes

NF is a genetic condition. That means the “cause” is a change (variant) in a gene that normally slows cell growth in nerves. Below are 20 clear causes and contributors, grouped so they make sense. Some causes apply to NF1, some to NF2-related schwannomatosis, and some to SMARCB1/LZTR1-related schwannomatosis.

1. Inherited variant from a parent.
   One parent has NF and passes the changed gene to the child. Each child has a 1-in-2 chance (50%) of inheriting it because these conditions are usually autosomal dominant. NCBI+1

2. New (de novo) variant in the child.
   No parent has NF, but a new gene change happens in the egg or sperm or very early after conception. This is common in NF1 and NF2. NCBI+1

3. Loss-of-function changes in the NF1 gene.
   NF1 makes a protein (neurofibromin) that slows growth signals. When the gene is damaged, growth signals are too strong. Types of damaging changes include nonsense, frameshift, splice, or large deletions. NCBI

4. Large NF1 microdeletion (“contiguous gene” deletion).
   A bigger chunk of chromosome 17 that includes NF1 is missing. This can cause more numerous or severe features. NCBI

5. Missense change in a critical NF1 domain.
   Some single-letter changes in key parts of NF1 still reduce function enough to cause disease. NCBI

6. Two-hit tumor formation in NF1.
   People inherit one changed NF1 copy in every cell. A second change happens later in certain cells, which then form neurofibromas or plexiform neurofibromas. NCBI

7. NF2 gene changes that disable merlin.
   NF2 codes for merlin (schwannomin), a protein that controls cell shape and stops growth. When merlin is missing or broken, schwannomas and meningiomas can develop. NCBI

8. Two-hit tumor formation in NF2-related schwannomatosis.
   As with NF1, a second “hit” in tumor cells leads to growth of vestibular and other schwannomas. NCBI

9. SMARCB1 gene variants.
   SMARCB1 helps control how DNA is packaged and read. Changes can cause multiple schwannomas and chronic pain. PubMed

10. LZTR1 gene variants.
    LZTR1 is another gene that, when changed, raises risk of multiple schwannomas outside the vestibular nerves. PubMed

11. Mosaicism (post-zygotic mutation).
    The gene change happens after the very first cell divisions, so only some body parts are affected. This can cause “segmental” or patchy NF signs. PubMed

12. Parental germline mosaicism.
    A parent has the change only in some egg or sperm cells. The parent looks unaffected, but a child can still inherit NF. NCBI

13. RAS/MAPK pathway over-activation in NF1.
    When neurofibromin is lost, the RAS pathway is over-active, which drives tumor growth and pigment changes. NCBI

14. Hippo/cytoskeleton signaling disturbance in NF2.
    Loss of merlin affects contact inhibition and cell-to-cell signals, allowing schwann cells to overgrow. NCBI

15. Second gene modifiers.
    Some people with the same main gene change have milder or more severe disease because of other background genes that modify risk. Researchers continue to study these effects. NCBI

16. Age-related tumor risk.
    Even with the same gene change, certain tumors become more likely with age (for example, vestibular schwannomas in NF2-related disease). NCBI

17. Hormonal and growth phases.
    Tumors may grow faster during puberty or pregnancy, likely due to growth and hormonal signals. This is seen clinically even though the core cause is genetic. NCBI

18. Radiation as a tumor promoter (rare context).
    Prior radiation can sometimes promote nerve-sheath tumors in people with NF1. Because of this risk, radiation is used cautiously. NCBI

19. Second, unrelated tumor gene changes.
    In a few cases, separate gene mistakes appear in tumors, adding to growth or transformation risk (for example, malignant peripheral nerve sheath tumor in NF1). NCBI

20. Chromosome 22 mechanisms in schwannomatosis.
    Many schwannomatosis forms involve changes on chromosome 22 (NF2, SMARCB1, or other 22q genes), fitting the pattern of multiple “hits” in the pathway. PubMed

---

Common Symptoms and Signs

Symptoms differ by type and person. Some people have only skin findings. Others have nerve tumors that cause pain or functional problems. Here are 15 common features explained simply.

1. Café-au-lait spots.
   Flat, light-brown skin patches that often appear in early childhood in NF1. They are painless and harmless but help doctors suspect NF1. NCBI

2. Freckling in body folds.
   Tiny freckles in the armpits or groin (intertriginous freckling) are classic for NF1. NCBI

3. Cutaneous neurofibromas.
   Soft, skin-level bumps that are benign nerve-sheath tumors. They may itch or be tender but are usually not dangerous. NCBI

4. Plexiform neurofibromas (NF1).
   Larger, deeper tumors along bigger nerves. They can cause pain, visible swelling, or pressure on nearby structures. A small number may turn cancerous over time. NCBI

5. Lisch nodules (NF1).
   Tiny, harmless spots on the iris of the eye seen with a slit-lamp exam. They help confirm NF1. NCBI

6. Optic pathway glioma (NF1).
   A benign brain tumor on the optic nerve that can reduce vision in children. Many are monitored; some need treatment. NCBI

7. Bone changes (NF1).
   Scoliosis, bowing of the long bones, or a defect near the eye socket (sphenoid wing dysplasia) may occur. NCBI

8. Learning or attention problems (NF1).
   Some children have learning difficulties or ADHD. Support in school helps. NCBI

9. Headache or seizures (NF1).
   A minority have headaches or seizures related to brain involvement. NCBI

10. High blood pressure (NF1).
    This can be due to renal artery narrowing or a rare adrenal tumor (pheochromocytoma). NCBI

11. Hearing loss (NF2-related).
    Hearing often declines due to vestibular schwannomas. Ringing in the ears (tinnitus) and balance trouble are common. NCBI

12. Balance problems (NF2-related).
    Dizziness, unsteadiness, or frequent falls may occur as vestibular tumors grow. NCBI

13. Eye issues in NF2-related disease.
    Early cataracts or visual changes can occur. NCBI

14. Painful peripheral schwannomas (SMARCB1/LZTR1-related).
    Deep, focal nerve pain from tumors along limbs or trunk is a common complaint. PubMed

15. Numbness or weakness from nerve compression.
    Any NF type can cause pressure on nearby nerves, leading to tingling, numbness, or weakness in the supplied area. NCBI+1

---

Diagnostic Tests

Doctors combine history, physical exam, and targeted tests. The newer criteria include genetic testing in many situations. Below are 20 tests grouped into five categories, each with a plain-English explanation.

A) Physical Exam

1. Full skin examination.
   The doctor looks carefully for café-au-lait spots, axillary/groin freckling, and skin neurofibromas. Pattern, number, and size help decide if criteria are met. Nature

2. Eye examination with slit-lamp (office-based).
   An ophthalmologist checks for Lisch nodules and for signs of optic pathway problems. This exam is painless and quick. NCBI

3. Neurological examination.
   Reflexes, strength, sensation, coordination, and gait are checked to look for nerve compression or brain/spinal involvement. NCBI

4. Hearing and cranial nerve screening.
   Bedside checks of hearing and facial movement can flag vestibular schwannomas, especially in NF2-related disease. NCBI

5. Blood pressure and growth charting.
   Blood pressure helps screen for renal artery stenosis or pheochromocytoma in NF1. Height, weight, and head size trends matter in children. NCBI

B) Manual / Bedside Tests

6. Rinne and Weber tuning-fork tests.
   Simple bedside hearing tests help tell if hearing loss is nerve-related (suggesting vestibular schwannoma). Abnormal results lead to full audiology testing. NCBI

7. Romberg and tandem gait tests.
   Standing with feet together and walking heel-to-toe check balance pathways that are often affected in NF2-related disease. NCBI

8. Manual muscle testing (MMT).
   Hands-on strength testing can reveal weakness from nerve compression by plexiform neurofibromas or spinal tumors. NCBI

9. Adam’s forward bend test (for scoliosis).
   A simple spine check for rib hump or curvature in children with NF1. Abnormal screens prompt imaging. NCBI

10. Palpation of nerve tracts and nodules.
    Gentle feeling along limbs and trunk can detect tender, mobile nodules that suggest peripheral schwannomas or neurofibromas. NCBI

C) Laboratory and Pathology

11. Germline genetic testing (blood or saliva).
    A panel can look for variants in NF1, NF2, SMARCB1, LZTR1, and other related genes. This helps confirm the specific NF type, especially with the 2021–2022 updated criteria. NaturePubMed

12. Tumor genetic testing (somatic testing).
    Testing tumor tissue can find the “second hit” and the exact gene involved in schwannomatosis when blood testing is negative. PubMed

13. Pathology of biopsied tumors.
    If a tumor is removed or sampled, the lab confirms if it is a neurofibroma, schwannoma, meningioma, or something else. Special stains and markers guide the diagnosis. NCBI

14. Plasma-free or 24-hour urine metanephrines (NF1).
    These lab tests screen for a catecholamine-secreting tumor (pheochromocytoma) when there is high blood pressure, headache, sweating, or palpitations. NCBI

D) Electrodiagnostic Tests

15. Formal audiology (pure-tone, speech testing).
    Defines the degree and type of hearing loss in suspected NF2-related disease and guides timing of imaging or treatment. NCBI

16. Auditory brainstem response (ABR).
    ABR measures how sound signals travel to the brainstem and can detect vestibular nerve problems when MRI access is limited or as a complement to imaging. NCBI

17. Nerve conduction studies and electromyography (NCS/EMG).
    These tests check nerve and muscle function if numbness, tingling, or weakness suggests compression by a peripheral tumor. NCBI

E) Imaging Tests

18. MRI of the brain with internal auditory canals.
    This is the best test to look for vestibular schwannomas, meningiomas, and other brain tumors. It is central in NF2-related schwannomatosis. NCBI

19. MRI of the spine.
    Looks for spinal schwannomas, ependymomas, or neurofibromas that could compress the cord or nerve roots. NCBI

20. Whole-body MRI or targeted regional MRI.
    Helpful in NF1 to map plexiform neurofibromas and in schwannomatosis to look for widespread tumors. It helps plan follow-up and surgery. NCBIPubMed

Non-pharmacological treatments

Each item explains what it is, why we do it (purpose), and how it helps (mechanism) in simple terms.

1. Lifelong multidisciplinary follow-up
   What: Annual visits with a team (neurology, dermatology, ophthalmology, ENT/audiology, oncology/orthopedics/psychology as needed).
   Purpose: Find problems early; decide when to treat; support daily life.
   Mechanism: Regular checks of skin, blood pressure, eyes, hearing, nerves, spine, and tumor symptoms catch complications early—like vision changes in children (optic pathway glioma) or hearing change in NF2. Evidence-based surveillance frameworks exist for NF1. PMC

2. Genetic counseling (with or without genetic testing)
   What: A specialist explains inheritance, testing, and family planning options.
   Purpose: Understand 50% transmission risk and options such as prenatal or preimplantation genetic testing.
   Mechanism: Clarifies risks and supports informed decisions; confirms the exact NF type when testing is done. PMCPubMed

3. Educational and learning support
   What: School accommodations, speech/occupational therapy, attention-support strategies.
   Purpose: Help with attention, learning, and executive function issues that are common in NF1.
   Mechanism: Structured teaching, therapy, and assistive tools improve school performance and daily functioning. PMC

4. Psychological therapy (including CBT)
   What: Counseling to manage anxiety, low mood, body-image, and chronic pain stress.
   Purpose: Improves coping, sleep, and social participation.
   Mechanism: CBT reframes pain and appearance-related thoughts, reduces avoidance, and builds resilience.

5. Comprehensive pain program
   What: A plan combining pacing, gentle activity, relaxation, heat/ice, TENS, and sleep hygiene.
   Purpose: Reduce day-to-day pain and flare-ups without relying only on pills.
   Mechanism: Gradual conditioning and nervous-system “down-training” lower pain sensitivity over time.

6. Physical therapy
   What: Tailored stretches, strengthening, balance, and posture work.
   Purpose: Protect joints and nerves, improve walking and stamina; help after tumor or spine surgery.
   Mechanism: Stronger muscles support the spine and reduce pressure on painful areas.

7. Occupational therapy
   What: Practical strategies, supports, and device advice for daily tasks.
   Purpose: Keep independence in school, work, and self-care.
   Mechanism: Energy-saving techniques and ergonomic changes reduce pain and strain.

8. Low-impact exercise plan
   What: Walking, swimming, cycling, yoga/taichi—3–5 days/week.
   Purpose: Support heart health, mood, bone strength, and weight.
   Mechanism: Regular movement reduces inflammation and improves nerve-related symptoms indirectly.

9. Sleep optimization
   What: Consistent schedule, screen curfew, dark room; evaluate snoring/sleep apnea when present.
   Purpose: Better sleep reduces pain sensitivity, brain fog, and irritability.
   Mechanism: Restorative sleep normalizes pain pathways and hormones.

10. Skin care & sun sense
    What: Gentle cleansers, moisturizer, sunscreen, and regular skin self-checks.
    Purpose: Keep skin comfortable; notice new or changing bumps earlier.
    Mechanism: Healthy skin barrier and routine checks help spot rapid changes that need review.

11. Cutaneous neurofibroma removal (office dermatology)
    What: Shave excision, electrodessication, or CO₂ laser to flatten or remove bothersome skin bumps.
    Purpose: Improve comfort, snagging/bleeding, and body image.
    Mechanism: Physically removes excess tumor tissue at the skin surface; multiple sessions may be needed. genturis.eu

12. Topical therapies for skin neurofibromas (specialist use)
    What: Small studies of topical sirolimus gel or investigational topical MEK-inhibitor (NFX-179).
    Purpose: Try to reduce redness/itch or shrink treated lesions.
    Mechanism: Sirolimus down-regulates mTOR signaling; topical MEK blocks MEK/ERK signaling in NF1-mutant cells. Early data only—discuss risks/benefits with your dermatologist. PubMed+1

13. Hearing aids (NF2-related schwannomatosis)
    What: Amplification devices tailored by audiology.
    Purpose: Improve hearing and communication when tumors impact the hearing nerve.
    Mechanism: Boosts sound to compensate for nerve signal loss.

14. Cochlear implant (selected NF2 cases)
    What: A device placed surgically to stimulate the cochlear nerve.
    Purpose: Restore useful hearing when the cochlear nerve still conducts signals.
    Mechanism: Converts sound to electrical impulses sent to the inner ear’s nerve fibers. PMC

15. Auditory brainstem implant (ABI)
    What: A surgical implant that stimulates the brainstem hearing pathway directly.
    Purpose: Provide sound awareness when the cochlear nerve is no longer functional.
    Mechanism: Electrodes on the cochlear nucleus bypass the damaged nerve. PMC

16. Vestibular (balance) rehabilitation
    What: Exercises to retrain balance after tumor growth, surgery, or hearing interventions.
    Purpose: Reduce dizziness, unsteadiness, and falls.
    Mechanism: Repeated, graded balance challenges re-educate the brain.

17. Low-vision care (NF1)
    What: Early and regular eye exams in childhood; low-vision aids if needed.
    Purpose: Catch optic pathway glioma effects early; support reading and school function.
    Mechanism: Age-appropriate testing and aids reduce disability from vision loss. PMC

18. Orthopedic management
    What: Bracing, shoe inserts, or surgery for scoliosis, tibial dysplasia, or limb differences.
    Purpose: Preserve function, reduce pain, and prevent progressive deformity.
    Mechanism: Mechanical support and, when needed, corrective operations.

19. Nutrition & weight management
    What: Balanced diet pattern (vegetables, fruits, whole grains, lean protein, healthy fats).
    Purpose: Support energy, bone health, wound healing, and blood pressure.
    Mechanism: Adequate protein, vitamin D/calcium, and fiber help the body cope with chronic disease.

20. Minimize unnecessary radiation exposure
    What: Prefer MRI over CT when feasible; avoid radiotherapy for benign NF1 lesions when alternatives exist.
    Purpose: Reduce the small but real risk of radiation-induced tumors, to which NF1 patients may be more vulnerable.
    Mechanism: Limiting ionizing radiation lowers long-term secondary cancer risk; major guidelines advise avoiding radiotherapy for NF1 low-grade glioma when possible. The LancetScienceDirect

---

Drug treatments

Important: medication choices are individualized. Doses below are typical references—not personal medical advice.

1. Selumetinib (KOSELUGO®) — MEK inhibitor for NF1 plexiform neurofibromas (PN); FDA-approved for children ≥2 years with symptomatic, inoperable PN.
   Dose/Time: 25 mg/m² by mouth twice daily on an empty stomach; continue while helping and tolerated.
   Purpose: Shrink PN and relieve PN-related problems (pain, disfigurement, motor or airway issues).
   Mechanism: Blocks MEK in the RAS-MAPK pathway hyperactive in NF1 tumors.
   Common side effects: rash/acne, diarrhea, nausea, mouth sores, swelling, ↑CK; warnings include heart function and eye issues (need baseline and periodic checks). FDA Access Data

2. Mirdametinib (GOMEKLI™) — MEK inhibitor; FDA-approved 2025 for adults and children ≥2 years with symptomatic NF1 PN not completely resectable.
   Dose/Time: 2 mg/m² twice daily for 21 days of each 28-day cycle; continue while effective and tolerated.
   Purpose: Shrink PN and improve PN-related symptoms.
   Mechanism: Same pathway as above (MEK).
   Common side effects: rash, diarrhea, nausea, fatigue, muscle pain; warnings include ocular toxicity and left-ventricular dysfunction, with recommended baseline and periodic monitoring. FDA Access Data

3. Bevacizumab (anti-VEGF antibody) — Off-label for NF2-related vestibular schwannomas (VS).
   Dose/Time: Regimens in studies include 5 mg/kg IV every 2 weeks, 7.5 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks for induction followed by lower-dose maintenance.
   Purpose: Improve or stabilize hearing and sometimes shrink VS in NF2.
   Mechanism: Blocks VEGF, starving tumor blood supply and reducing edema.
   Common side effects: hypertension, proteinuria, bleeding risk, fatigue; careful monitoring required. nfnetwork.orgPubMedOxford Academic

4. Carboplatin + Vincristine (protocol-based chemotherapy) — Used for NF1-associated optic pathway glioma when vision is threatened.
   Dose/Time: Oncology protocols with weight/size-based dosing and cycles; not self-dosed.
   Purpose: Preserve vision by controlling tumor growth.
   Mechanism: Cytotoxic therapy targeting dividing tumor cells. (Your child’s oncology team individualizes dosing and monitoring.) The Lancet

5. Everolimus (mTOR inhibitor; off-label in NF)
   Purpose: Studied for some NF1-related tumors; may help select cases under specialist care.
   Mechanism: Inhibits mTOR signaling important for some tumor growth.
   Notes: Dosing/monitoring is specialist-led; common effects include mouth sores and infection risk (immune effects). (Evidence mixed; not routine.)

6. Topical sirolimus (dermatology, specialist compounded)
   Purpose: Early studies suggest it can soften or slightly flatten some cutaneous neurofibromas and ease itch.
   Mechanism: Local mTOR inhibition in treated lesions.
   Notes: Applied to selected lesions; irritation possible. PubMed

7. Gabapentin (neuropathic pain controller)
   Dose/Time: Start 100–300 mg at night, slowly increase to 300–600 mg three times daily as tolerated (typical range up to 3600 mg/day).
   Purpose: Reduce nerve-type pain and burning sensations from tumors pressing on nerves.
   Mechanism: Calms over-excited nerve signaling (α2δ calcium channel subunit).
   Common side effects: sleepiness, dizziness, swelling.

8. Pregabalin (neuropathic pain)
   Dose/Time: Commonly 75 mg twice daily, titrating to 150–300 mg twice daily.
   Purpose/Mechanism: Similar to gabapentin; sometimes better tolerated or simpler dosing.
   Side effects: sleepiness, dizziness, weight gain, edema.

9. Duloxetine (SNRI for neuropathic pain & mood)
   Dose/Time: 30 mg daily for a week, then 60 mg daily if tolerated.
   Purpose: Helps nerve pain and co-existing anxiety/low mood.
   Mechanism: Boosts serotonin/norepinephrine in pain pathways.
   Side effects: nausea, dry mouth, sleep change; avoid with certain other meds.

10. NFX-179 topical MEK-inhibitor gel (investigational)
    Purpose: In a 2024 clinical trial, treated cutaneous neurofibromas reduced in volume compared with placebo.
    Mechanism: Local MEK blockade in NF1-mutant skin tumors.
    Status: Research use only; discuss clinical trial options with your team. PubMed

Drug interactions tip: If you’re on selumetinib, avoid strong/moderate CYP3A4 inhibitors (and grapefruit products) unless your specialist adjusts the dose; follow the label guidance. FDA Access Data

---

Dietary “molecular” supplements

There is no supplement that treats or cures NF. If you choose supplements, do so with your clinician, especially if you take MEK inhibitors or chemotherapy.

1. Vitamin D3 (e.g., 1000–2000 IU/day; target a normal blood vitamin D level): supports bone and immune function.

2. Calcium (from food first; supplements only if diet is insufficient): supports bone, especially if mobility is limited.

3. Omega-3 (EPA/DHA) (e.g., ~1 g/day): general anti-inflammatory support; may help aches.

4. Magnesium (200–400 mg at night): may ease cramps and improve sleep.

5. Melatonin (1–5 mg at bedtime): helps sleep quality.

6. Alpha-lipoic acid (600 mg/day): sometimes used for nerve pain; check for thyroid/diabetes interactions.

7. B-complex (B12/folate if low): corrects deficiencies that worsen fatigue or neuropathy.

8. CoQ10 (100–200 mg/day): general mitochondrial support; evidence is modest.

9. Curcumin (500–1000 mg/day with piperine unless on anticoagulants): anti-inflammatory potential.

10. Probiotic foods/supplement: gut support if antibiotics or stress upset digestion.

Again: these are optional, and quality varies. Always screen for drug–supplement interactions.

---

Advanced/biologic” or regenerative-style approaches

Straight talk: there are no approved “immunity-booster,” stem-cell, or regenerative drugs for NF at this time. What does exist are targeted/biologic therapies and implants that can restore function in specific situations.

1. Selumetinib (MEK inhibitor; label-approved for NF1 PN) — see dosing above.

2. Mirdametinib (MEK inhibitor; label-approved 2025 for NF1 PN) — see dosing above. FDA Access Data+1

3. Bevacizumab (anti-VEGF) for NF2 vestibular schwannomas — improves hearing in a meaningful fraction; typical study doses 5–10 mg/kg IV at 2–3-week intervals. New England Journal of MedicinePubMed

4. Everolimus/Sirolimus (mTOR inhibitors; off-label) — considered in select tumor types under specialist protocols.

5. Topical MEK or mTOR agents for skin lesions (research/dermatology) — localized effect with early supportive data. PubMed

6. Hearing implants (cochlear implant or ABI) in NF2 — restore sound awareness and, in some, speech understanding when hearing nerves are damaged. (Surgery plus device programming.) PMC

---

Surgeries

1. Removal of cutaneous neurofibromas
   Procedure: Office-based shave/excision, electrodessication, or CO₂ laser for multiple lesions.
   Why: Reduce snagging, bleeding, itch, and improve appearance/comfort. Recurrence is possible. genturis.eu

2. Debulking or resection of a plexiform neurofibroma
   Procedure: Careful surgery in an experienced center; sometimes staged.
   Why: Relieve compression (pain, weakness, airway, bowel/bladder issues) or significant disfigurement when medicines are not enough.

3. Spine surgery
   Procedure: Decompression (laminectomy) ± stabilization when tumors or scoliosis compress the cord/nerve roots.
   Why: Protect movement and sensation; relieve severe pain or weakness.

4. Vestibular schwannoma surgery (NF2)
   Procedure: Microsurgical removal via approach chosen to balance tumor control and hearing/facial-nerve preservation.
   Why: Needed for large tumors, brainstem compression, or when other options fail.

5. Cochlear implant or Auditory brainstem implant
   Procedure: Implant under general anesthesia; device programmed later.
   Why: Restore sound detection and, for some, speech understanding in NF2. PMC

Note on radiosurgery: Stereotactic radiosurgery is sometimes used for NF2 vestibular schwannomas in place of surgery. Contemporary reviews compare outcomes; choice depends on tumor size, growth, hearing goals, and patient preference. Discuss in an NF-experienced center.

---

Prevention strategies

1. Know your NF type (NF1 vs NF2-related vs LZTR1/SMARCB1 schwannomatosis) and follow the right surveillance plan. PMC

2. Annual check-ups with an NF-experienced team; earlier review for new symptoms. PMC

3. Women with NF1: follow earlier breast-cancer screening—annual MRI from age 30–50 (then follow national guidance)—because risk is higher than average.

4. Limit unnecessary radiation (prefer MRI, avoid radiotherapy for benign NF1 tumors when possible). The Lancet

5. Control blood pressure (NF1 is linked with vascular issues; treat promptly).

6. Don’t smoke (smoking worsens vascular and cancer risks).

7. Healthy weight, regular activity, and good sleep to support recovery and pain control.

8. Vaccinations up-to-date (especially if on medicines that affect immunity).

9. Skin and nerve self-checks: note new, fast-growing, hard, or painful lumps; track numbness/weakness changes.

10. Prompt eye and hearing tests for new symptoms (children with NF1: routine eye checks; NF2: audiology). PMC

---

When to see a doctor urgently

• Rapidly enlarging, hard, or very painful lump (possible MPNST—needs urgent evaluation). Cancer.gov

• New or worsening weakness, numbness, or bladder/bowel changes.

• Sudden or progressive hearing loss, tinnitus, balance trouble (especially in NF2). NCBI

• New vision problems, eye turning, or headaches with vomiting (especially in a child with NF1). PMC

• Fevers/skin infection around a neurofibroma, or wound problems after treatment.

---

What to eat & what to avoid

Eat more of:

1. Vegetables and fruits (aim colorful variety).

2. Whole grains (oats, brown rice).

3. Lean proteins (fish, poultry, legumes).

4. Healthy fats (olive oil, nuts, seeds).

5. Calcium sources (dairy or fortified alternatives).

6. Vitamin-D foods (fatty fish; consider supplement if low).

7. Fiber-rich foods for gut health (beans, lentils).

8. Water and unsweetened drinks.

9. Fermented foods (yogurt, kefir).

10. Spices like turmeric/ginger in cooking (gentle anti-inflammatory flavor).

Limit/avoid:

1. Excess salt (protects blood pressure).

2. Ultra-processed snack foods and sugary drinks.

3. Excess alcohol (worsens sleep and BP).

4. Energy drinks (jittery sleep/palpitations).

5. Very high-dose unproven supplements.

6. Grapefruit products if you use selumetinib (CYP3A4 interaction). FDA Access Data

7. Smoking/vaping (not food—but vital).

8. “Detox” products with unknown ingredients.

9. Raw/high-risk foods if on immune-affecting drugs (food safety first).

10. Anything that consistently worsens your personal symptoms.

---

Frequently asked questions (FAQs)

1) What’s the difference between NF1, NF2-related schwannomatosis, and “schwannomatosis”?
NF1 mainly causes neurofibromas and skin/eye/bone features; NF2-related causes vestibular schwannomas and other CNS tumors; LZTR1/SMARCB1 schwannomatosis mainly causes multiple schwannomas and pain. Names and criteria were updated in 2022 to reduce confusion. PubMed

2) Is NF contagious or caused by something I did?
No. It’s a genetic condition present from birth.

3) If I have NF, what’s the chance my child will have it?
Each pregnancy has a 50% chance if you carry the condition. About half of people with NF1 are the first in their family due to a new variant. A genetics professional can help with testing options. PMC

4) Does everyone with NF get tumors that need treatment?
No. Many tumors never cause trouble. Treatment is aimed at symptomatic or risky tumors.

5) Can NF1 skin bumps turn into cancer?
Most cutaneous neurofibromas stay benign. Deep plexiform neurofibromas can rarely transform to MPNST—watch for rapid change, pain, or hardness and seek prompt review. Lifetime risk in NF1 is roughly 8–13% for MPNST. Cancer.gov

6) Are there medicines that shrink NF1 plexiform neurofibromas?
Yes. Selumetinib and mirdametinib (both MEK inhibitors) can shrink PN and improve symptoms in many patients. FDA Access Data+1

7) Can medicines help hearing in NF2?
Bevacizumab has improved hearing for a significant fraction of NF2 patients with growing vestibular schwannomas in clinical studies; dosing and monitoring are specialist-led. PubMed

8) Are there risks with radiation (CT scans or radiotherapy)?
Yes. People with NF1 already have higher tumor risk, so clinicians try to limit ionizing radiation (use MRI when feasible; avoid radiotherapy for benign NF1 brain tumors if possible). The Lancet

9) Why do some experts recommend early breast screening in NF1?
Women with NF1 have higher breast-cancer risk at younger ages, so guidelines advise annual MRI from age 30–50.

10) Can I exercise?
Yes—strongly encouraged. Choose low-impact routines and build gradually; your team can tailor advice after surgery or if you have weakness.

11) Will pregnancy make neurofibromas worse?
Skin neurofibromas can grow or appear during pregnancy in some people; your team will monitor and manage symptoms.

12) Are tattoos or piercings okay?
Discuss placement with your clinician—avoid areas with prominent neurofibromas or where future imaging/surgery access is likely.

13) Do supplements help?
No supplement has proven disease-modifying effects in NF. Some people use supportive supplements (vitamin D, omega-3) for general health—check interactions first (especially with MEK inhibitors).

14) What is “mosaic” NF?
When only some cells carry the NF variant, features may be limited to certain body regions. Genetic testing and careful examination can clarify this.

15) How do I find an experienced NF clinic or trials?
Ask your specialist, search national NF organizations, or academic centers with genetic tumor clinics. (They can also advise on clinical trials, including topical or systemic targeted therapies.) NCBI

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 15, 2025.